Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARCH 2: Abemaciclib + Fulvestrant vs Placebo + Fulvestrant in HR-positive, HER2-negative Advanced Breast Cancer
jRCT2080222563Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib + Fulvestrant with Placebo + Fulvestrant (2 arms). Started Jul 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222563.